T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Karussis, Dimitrios ^a   Shor, Hagai ^a   Yachnin, Julia ^a   Lanxner, Naama ^a   Amiel, Merav ^a   Baruch, Keren ^a   Keren Zur, Yael ^a   Haviv, Ofra ^a   Filippi, Massimo ^b   Petrou, Panayiota ^a   Hajag, Shalom ^a   Vourka Karussis, Urania ^a   Vaknin Dembinsky, Adi ^a   Khoury, Salim ^a   Abramsky, Oded ^a   Atlan, Henri ^a   Cohen, Irun R ^c   Abulafia Lapid, Rivka ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; MYELIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PLACEBO; PROTEOLIPID PROTEIN; T LYMPHOCYTE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADULT; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; BREATHING RATE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COGNITION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FEASIBILITY STUDY; FEMALE; HEART RATE; HUMAN; INJECTION SITE ERYTHEMA; IRRADIATION; LEUKOCYTE COUNT; MALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SIDE EFFECT; T LYMPHOCYTE; WALKING;

ADULT; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYMPHOCYTES; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MYELIN SHEATH; PEPTIDES; PHENOTYPE; PLACEBOS; RECURRENCE; T-LYMPHOCYTES; TIME FACTORS; VACCINATION;

EID: 84871265763     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050478     Document Type: Article

References (25)

1. Steinman L, (2001) Multiple sclerosis: a two-stage disease. Nat Immunol 2: 762-764.
2. Hellings N, Raus J, Stinissen P, (2002) Insights into the immunopathogenesis of multiple sclerosis. Immunol Res 25: 27-51.
3. Ben-Nun A, Wekerle H, Cohen IR, (1981) Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 292: 60-61.
4. Zhang J, Medaer R, Stinissen P, Hafler D, Raus J, (1993) MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 261: 1451-1454.
5. Quintana FJ, Cohen IR, (2006) Anti-ergotypic immunoregulation. Scand J Immunol 64: 205-210.
6. Mimran A, Cohen IR, (2005) Regulatory T cells in autoimmune diseases: anti-ergotypic T cells. Int Rev Immunol 24: 159-179.
7. Quintana FJ, Mimran A, Carmi P, Mor F, Cohen IR, (2008) HSP60 as a target of anti-ergotypic regulatory T cells. PLoS One 3: e4026.
8. Lider O, Reshef T, Beraud E, Ben-Nun A, Cohen IR, (1988) Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 239: 181-183.
9. Jiang H, Kashleva H, Xu LX, Forman J, Flaherty L, et al. (1998) T cell vaccination induces T cell receptor Vbeta-specific Qa-1-restricted regulatory CD8(+) T cells. Proc Natl Acad Sci U S A 95: 4533-4537.
10. Hellings N, Raus J, Stinissen P, (2004) T-cell vaccination in multiple sclerosis: update on clinical application and mode of action. Autoimmun Rev 3: 267-275.
11. Vandenbark AA, Abulafia-Lapid R, (2008) Autologous T-cell vaccination for multiple sclerosis: a perspective on progress. BioDrugs 22: 265-273.
12. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, et al. (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50: 398-402.
13. Comi G, Filippi M, Wolinsky JS, (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49: 290-297.
14. Achiron A, Lavie G, Kishner I, Stern Y, Sarova-Pinhas I, et al. (2004) T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin Immunol 113: 155-160.
15. Hermans G, Denzer U, Lohse A, Raus J, Stinissen P, (1999) Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. J Autoimmun 13: 233-246.
16. Hermans G, Medaer R, Raus J, Stinissen P, (2000) Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations. J Neuroimmunol 102: 79-84.
17. Medaer R, Stinissen P, Truyen L, Raus J, Zhang J, (1995) Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet 346: 807-808.
18. Stinissen P, Zhang J, Medaer R, Vandevyver C, Raus J, (1996) Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data. J Neurosci Res 45: 500-511.
19. Zhang JZ, Rivera VM, Tejada-Simon MV, Yang D, Hong J, et al. (2002) T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol 249: 212-218.
20. Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ, (2000) Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol 164: 4011-4017.
21. Zang YC, Hong J, Tejada-Simon MV, Li S, Rivera VM, et al. (2000) Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol 30: 908-913.
22. Hong J, Zang YC, Nie H, Zhang JZ, (2006) CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis. Proc Natl Acad Sci U S A 103: 5024-5029.
23. Buenafe AC, Tsaknaridis L, Spencer L, Hicks KS, McMahan RH, et al. (2004) Specificity of regulatory CD4+CD25+ T cells for self-T cell receptor determinants. J Neurosci Res 76: 129-140.
24. Vandenbark AA, Culbertson NE, Bartholomew RM, Huan J, Agotsch M, et al. (2008) Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 123: 66-78.
25. Correale J, Lund B, McMillan M, Ko DY, McCarthy K, et al. (2000) T cell vaccination in secondary progressive multiple sclerosis. J Neuroimmunol 107: 130-139.